Sleeping Beauty transposon mutagenesis identifies genes that cooperate with mutant Smad4 in gastric cancer

Haruna Takeda1, Alistair G Rust2, Jerrold M Ward3

  • 1Division of Genomics and Genetics, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673; Department of Pathology, School of Medicine, Kanazawa Medical University, Ishikawa 920-0293, Japan;

Insights

This study used Sleeping Beauty transposon mutagenesis in mice to identify genes driving gastric cancer (GC) development. It revealed key pathways and identified LDL receptor-related protein 1B (LRP1B) as a novel GC tumor suppressor gene.

Area of Science:

  • Oncogenomics
  • Cancer Biology
  • Molecular Genetics

Background:

  • Mutations in SMAD4 are linked to gastrointestinal cancer, the third leading cause of cancer deaths.
  • Gastric cancer (GC) development is driven by complex genetic alterations.
  • Understanding these drivers is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To identify novel genes and pathways that drive gastric cancer (GC) development in the context of SMAD4 mutations.
  • To compare findings from a mouse model with human GC genomic data.
  • To discover new candidate tumor suppressor genes for GC.

Main Methods:

  • Utilized Sleeping Beauty (SB) transposon mutagenesis in Smad4(+/-) mutant mice to screen for GC drivers.
  • Performed pathway analysis on identified genes.
  • Conducted comparative oncogenomic filtering against human GC mutation data.

Main Results:

  • Identified 59 candidate GC trunk drivers and numerous progression genes.
  • Found that SB-identified drivers include known human GC genes like PTEN, SMAD4, RNF43, and NF1.
  • Pathway analysis revealed deregulation in WNT, TGF-β, PI3K-PTEN signaling, and chromatin organization.
  • Identified LDL receptor-related protein 1B (LRP1B) as a novel candidate GC tumor suppressor gene, with frequent mutations and deletions in human GC samples.

Conclusions:

  • SB mutagenesis is effective in cataloging cooperative molecular mechanisms in SMAD4-induced GC.
  • The study identified LRP1B as a significant, previously unrecognized GC tumor suppressor.
  • Findings highlight potential new therapeutic targets and diagnostic markers for human GC.